Dr. Karin Berger
PhD
Biography
Karin Berger is a senior researcher at the Ludwig-Maximilian-University Munich, hospital department oncology / haematolgy and Insitute for Medical Informatics, Processing, Biometry and Epidemiology. She is head of the working group outcomes research, health economics and access. Her current research interest is on clinical and patient reported outcomes research, treatment pattern analysis, patient flow analyses, health economic evaluation analyses, real world data applications and HTA assessments. Before joining the Med III Karin Berger has been a researcher at the department for transfusion medicine, cell therapeutics and hemostasis at the University Hospital of Munich for 17 years. In this position she has been involved in national and international outcomes research studies and health economic analyses on very cost intensive treatments with blood and blood products. Further she has been actively involved in discussions with payers and clinicians on optimization strategies of these expensive treatments.
Key Institutions
-
Ludwig-Maximilian-University Munich
Oncology / Haematolgy and Insitute for Medical Informatics, Processing, Biometry and Epidemiology
Munich, Germany
Current Positions/Chairs
-
Senior Researcher
Publications
Challenges associated with access to recently developed hemophilia treatments in routine care – healthcare professionals’ perspectives.
Authors
Berger K, O’Rourke RH, Matteo Nicola DD, Batorova A, Kavakli K, Mannuccio PM, Wolfgang Schramm W, Rhonda BL, Aledort L on behalf of the International Prophylaxis Study Group.
Citation
Hematologica. 2024 Mar 1; 110(3):673-682. DOI: 10.3324/haematol.2024.285647
Are all licensed hemostatic agents for hemophilia therapy accessible to patients? Letter to the Editor
Authors
Berger K, Batorova A, Bohn RL, di Minno M, Mannucci P, Kavakli K, Schramm W, Aledort L on behalf of the International Prophylaxis Study Group
Citation
Haemophilia. 2022; 28:e256–e258. DOI: 10.1111/hae.14660
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.
Authors
Berger K, Feldman BM, Wasserman J, Schramm W, Blanchette VS, Fischer K on behalf of the Outcome Measures Expert Working Group of the IPSG
Citation
Haematologica; March 2016 101: 266-268
Hemophilia Prophylaxis: How can we justify the costs?
Authors
Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, and Schramm W.
Citation
Haemophilia 2012 Sept; 18 (5): 680-684.
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG).
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Citation
Haemophilia 2008, 14 (S2), 133 # 24 PO 17.
A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG)
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of the International Prophylaxis Study Group.
Authors
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Mantovani L, Hoots K,, Schramm W, van Hout BA, Willan AR, and Feldman BM.
Citation
Haemophilia 2008 Jan; 14 (1):127 -132.